Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC

Summary

Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who achieved at least a partial response (PR) following platinum-based first-line therapy.

Timeline

Start

2014-03

Primary completion

2016-11

Completion

2017-10-05

Outcome

Missed primary endpoint

paper The IMPULSE study showed no relevant effect of lefitolimod on the main efficacy end point OS in the ITT PMID 30137193 ↗

Publications

• Results Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Domine Gomez M, Kollmeier J, Sadjadian P, Frohling KP, Huber RM, Wolf M; IMPULSE study team. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. Ann Oncol. 2018 Oct 1;29(10):2076-2084. doi: 10.1093/annonc/mdy326.

Drugs

Indications